A new study published in Frontiers in Oncology has revealed that a combination of two readily available dietary supplements – N-acetylcysteine (NAC) and epigallocatechin gallate (EGCG) – demonstrates a significant ability to reduce brain tumor growth. Researchers found a 33% reduction in tumor size in preclinical models when these supplements were administered together.
The research, conducted by scientists at the University of Texas Health Science Center at San Antonio, focused on glioblastoma, an aggressive and difficult-to-treat form of brain cancer. Glioblastoma has a particularly poor prognosis, with a median survival rate of just 15 months after diagnosis. Current treatment options, including surgery, radiation, and chemotherapy, often prove insufficient in halting the tumor’s progression.
Synergistic Effect
The study highlights a synergistic effect between NAC and EGCG. NAC, an amino acid, is known for its antioxidant properties and its role in glutathione production, a crucial molecule for cellular defense. EGCG, a polyphenol found abundantly in green tea, has demonstrated anti-cancer properties in numerous studies. However, when combined, their impact on glioblastoma cells was markedly enhanced.
Researchers discovered that the combination disrupts the metabolic pathways of glioblastoma cells, specifically targeting their ability to generate energy. Cancer cells often exhibit altered metabolism, relying heavily on specific pathways for rapid growth. By interfering with these pathways, NAC and EGCG effectively starve the tumor cells, slowing their proliferation and promoting cell death.
“We observed that the combination of NAC and EGCG significantly impaired the ability of glioblastoma cells to thrive,” explained Dr. Siva Kumar, lead author of the study. “This suggests a potential therapeutic strategy that could complement existing treatments and improve outcomes for patients.”
The study involved both in vitro (laboratory) experiments using glioblastoma cell lines and in vivo (animal) studies using mouse models. In the animal studies, mice treated with the NAC-EGCG combination exhibited smaller tumor volumes and prolonged survival compared to control groups.
While these findings are promising, researchers emphasize that this is still early-stage research. Further studies, including clinical trials in humans, are necessary to confirm the efficacy and safety of this supplement combination as a cancer treatment. The optimal dosage and long-term effects also need to be investigated.
The team is currently planning Phase I clinical trials to assess the feasibility and safety of administering NAC and EGCG to glioblastoma patients. If successful, this could pave the way for larger-scale trials to evaluate the treatment’s effectiveness. The researchers caution against self-treating with these supplements, emphasizing the importance of medical supervision and adherence to established treatment protocols. This research offers a glimmer of hope in the fight against this devastating disease, suggesting that simple, accessible interventions may hold potential for improving patient outcomes.
Image Source: Google | Image Credit: Respective Owner
